H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on CorMedix (CRMD) to $18 from $17 and keeps a Buy rating on the shares post the Q3 report. With the acquisition of Melinta now closed, CorMedix has a more diversified business going into 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD: